About the Anti-Coagulant Drugs Market
Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.
Technavio’s analysts forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.Technavio's report, Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Anti-Coagulants Market in the US 2016-2020
Technavio recognizes the following companies as the key players in the Anti-Coagulants Market in the US: Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Daiichi Sankyo.
Other Prominent Vendors in the market are: Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., and Valeant Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “A trend to look forward to would be new therapeutic uses for anti-coagulant drugs. Using anticoagulants for purposes other than the normal anticoagulation effects will widen the scope of the market and help in gaining higher revenues. Heparin and related drugs are widely used for their anticoagulant activities. However, it has been identified that heparin exhibits anti-inflammatory activities and prevents the metastatic spread of tumor cells. Heparin exhibits anti-inflammatory activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase, all of which are involved in leukocyte recruitment into tissues. Similarly, research studies indicate that heparins acts as an inhibitor of cell adhesion and thereby elicit anti-metastatic activities.”
According to the report, a key growth driver would be the growing prevalence of coagulation disorders. Anticoagulants are prescribed in conditions such as AF, DVT, pulmonary embolism, stroke, clotting disorders, heart attack, and renal diseases. Cardiovascular disorders, kidney disorders, and strokes are becoming more prevalent due to unhealthy lifestyles among individuals, including a lack of physical activity, excessive alcohol consumption, and smoking. It is estimated that 900,000 people are affected each year by DVT or pulmonary embolism, and 60,000-100,000 individuals die of this condition in the US. They are a major cause of maternal and hospital deaths in the US. Heart diseases are the leading cause of death in the region, with an estimated 610,000 deaths reported every year.
Further, the report states that one challenge that could hamper market growth is the side effects associated with drugs.
Johnson & Johnson, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Armatheon Inc., Aspen, AstraZeneca, Bayer, Cellceutix, Cosmo Pharmaceuticals SA, CSL Behring, Eisai, GSK, Marathon Pharmaceuticals LLC, Ockham Biotech, Perosphere, Portola Pharmaceuticals, Sagent Pharmaceuticals Inc., The Medicines Company, Urigen Pharmaceuticals Inc., Valeant Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook